Functional consequence of MDR1 expression on imatinib intracellular concentrations
- 1 August 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 102 (3), 1142
- https://doi.org/10.1182/blood-2003-03-0993
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsBlood, 2003
- In vitro and in vivo models for assessing drug efflux transporter activityAdvanced Drug Delivery Reviews, 2003
- Mechanisms of resistance to imatinib mesylate in Bcr-Abl–positive leukemiasCurrent Opinion in Oncology, 2002
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2002
- Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceBlood, 2000
- Prognostic Value of P-Glycoprotein and Leukocyte Differentiation Antigens in Chronic Myeloid LeukemiaLeukemia & Lymphoma, 1998
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.JCI Insight, 1995
- Expression of the multidrug resistance gene in myeloid leukemiasLeukemia Research, 1990